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Low-dose intravenous calcitriol treatment of secondary hyperparathy.
roidism in hemodialysis patients. Intravenous calcitriol is known to
directly suppress P1'H secretion and release. We evaluated the effect of
four months of treatment with low-dose intravenous calcitriol on PTH
levels in 83 hemodialysis patients. The criteria for including patients in
the study were a serum P'FH levels at least four times the normal limit,
a serum total calcium less than 10 mg/dl and good control of the serum
phosphorus level. All patients underwent standard bicarbonate or
acetate dialysis; dialysate calcium level was maintained at the usual 3.5
mEq/liter concentration. Initial calcitriol dose was 0.87 0.02 (5EM) .tg(0.015 jzg/kg body wt) thrice weekly at the end of dialysis, and it was
reduced in case of hypercalcemia or elevated calcium-phosphate prod-
uct. Seven out of 83 patients dropped out during treatment. Among the
76 patients who completed the study, 58 (76%) showed a highly
significant decrease of intact PTH levels (average reduction 48%) and of
alkaline phosphatase levels after four months of therapy. Total serum
calcium increased slightly but significantly in the responder group but
remained unchanged in the non-responders. No significant changes in
ionized calcium levels could be detected, even in responders. Treat-
ment was well tolerated by patients, but 60% of them had transient
episodes of hyperphosphatemia. Mean serum phosphate was 4.95 mg/dl
at the beginning of the study. It increased significantly after four months
of treatment in patients who showed a decrease of PTH levels, although
it remained within acceptable limits, below 5.5 mg/dl. Twenty-eight of
76 patients (37%) reduced the dose of calcitriol because their calcium-
phosphate products exceeded 60. Low-dose intravenous calcitriol ther-
apy for secondary hyperparathyroidism in dialysis patients is safe and
may be highly effective in reducing serum PTH and alkaline phos-
phatase levels without significant increases of ionized calcium concen-
trations. However, the frequent occurrence of asymptomatic hyper-
phosphatemia indicates that similar precautions are needed for
intravenous and oral calcitriol administration.
After the discovery that the kidney is the major organ
responsible for the generation of calcitriol, the active form of
vitamin D [I], the treatment of renal osteodystrophy has been
greatly improved by the introduction in the clinical practice of
calcitriol itself and of its analogue, l-a-hydroxyvitamin D [2, 3].
Symptomatic patients affected by secondary hyperparathyroid-
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ism treated orally with active vitamin D metabolites show a
decrease in bone pain, improvement in muscle strength and
lowering of immunoreactive PTH and alkaline phosphatase
plasma levels; bone histology also improves. However, serum
PTH levels remain elevated in many patients despite normal-
ization of serum calcium levels. Moreover, hypercalcemia is
not uncommon in uremic patients treated with oral calcitriol
and calcium salts used as phosphate binders [4].
It has been shown that circulating I ,25-dihydroxycholecalcif-
erol directly inhibits the secretion of PTH, independent of
changes in serum calcium [5, 6]. This observation has been
substantiated by in vivo studies in which the intravenous
administration of calcitriol markedly reduced the serum levels
of PTH in hemodialysis patients [7, 8]. Some of these patients
did not previously respond to treatment with oral calcium
carbonate or with oral calcitriol. The greater suppressive effect
of intravenous calcitriol versus oral calcitriol in these patients
has been related to the higher serum concentration achieved
with the intravenous administration [7], considering that the
suppression of PTH secretion by calcitriol in vitro is dose
dependent [9]. PTH suppression following intravenous cal-
citriol is also dependent, in part, from an increased sensitivity
of the parathyroid gland to ambient calcium levels [10].
However, there have been no prospective controlled studies
comparing oral and intravenous calcitriol, and the retrospective
comparisons have always been with daily oral therapy rather
than the schedule used for intravenous therapy. Higher doses of
oral calcitriol can be given as pulses twice or thrice per week,
with the aim of obtaining higher levels of calcitriol in the
circulation [11]. A comparison of similar doses of pulse oral and
intravenous calcitriol could clarify the actual advantages of one
over the other treatment modality.
Long-term intravenous calcitriol treatment of secondary
hyperparathyroidism proved to be effective in studies where
relatively high doses of calcitriol have been used (1.0 to 2.5 p.g
three times per week) [7, 8]. Such doses determined an increase
of total calcium levels, while no effect on phosphate levels was
reported. The long term effects of low-dose intravenous admin-
istration of calcitriol have not been previously investigated. The
rationale for a low-dose intravenous calcitriol therapy arose
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from the observation that in previously published long-term
studies, very rarely could a dose higher than 1.5 ig per dialysis
session be administered for more than several weeks of treat-
ment. The purpose of this study was to evaluate the biochem-
ical response to a four months of intermittent therapy with
low-dose intravenous calcitriol in a large group of hemodialysis
patients with mild to severe secondary hyperparathyroidism.
Methods
Eighty-three stable patients who had been treated with he-
modialysis for greater than six months entered the study.
Patients were selected in five different dialysis units located in
four different geographic areas of Northern Italy: (1) Genova,
Ospedale San Martino, 21 patients; (2) Ferrara, Arcispedale
Sant'Anna, 20 patients; (3) Milano, Ospedale San Paolo, 15
patients, and Ospedale Predabissi-Melegnano, 6 patients; (4)
Como, Ospedale Sant'Anna, 21 patients. The number of pa-
tients represented for the four different geographic areas is
similar, and there were no significant differences in population
characteristics among the different centers.
The residual creatinine clearance in all patients was less than
1 mL/min. All patients underwent standard dialysis four to five
hours per session, three times per week using either bicarbon-
ate or acetate buffer and hollow fiber dialyzers. Patient ages
ranged from 20 to 75 years, with a mean age of 54 1.38 (sEM)
years; the mean dialytic age was 90 7.6 months (range 6 to
238).
Patients previously treated with oral calcitriol discontinued
treatment at least two months before starting intravenous
calcitriol. The criteria for including patients in the study were:
a serum PTH level at least four times the normal limit, mea-
sured using either an intact PTH (Como, Genova, Ferrara) or a
middle molecule PTH (Milano) assay; a serum total calcium less
than 10 mg/dl; and good control of the serum phosphorus levels
(4 to 6 mg/dl in at least 3 of the routine monthly determinations
during the previous 4 months). Dialysate calcium level was
maintained at the usual 3.5 mEq/Iiter concentration. Phosphate
binders were aluminum salts, calcium carbonate or a combina-
tion of the two drugs. Dosage was adjusted during treatment in
order to maintain serum phosphate concentrations below 6
mgldl, and calcium carbonate was reduced or discontinued in
case of hypercalcemia (serum calcium higher than 11 mg/dl).
Calcitriol was injected into the venous side of the dialysis
tubing at the end of hemodialysis three times a week for four
months. In all patients the initial dose was 0.015 pg/kg body
weight, which corresponds to I pg for a 70 kg subject.
Following the onset of a serum calcium level exceeding 11
mg/dl or a calcium times phosphate product greater than 60,
calcitriol was temporarily discontinued and was subsequently
reintroduced and maintained at half the previous dose.
Total and ionized calcium, phosphorus, albumin, alkaline
phosphatase, magnesium and serum PTH using two different
radioimmunoassays (RIA) were determined simultaneously at
the beginning, after two months and after four months of
treatment. Moreover, total serum calcium and phosphorus
levels were measured weekly during treatment in order to
promptly detect possible hypercalcemia and hyperphos-
phatemia. In cases of increased phosphate or calcium levels,
measurements were done at the beginning of each dialysis
session until normalization.
Table 1. Intact PTH levels during intravenous calcitriol therapy
Intact PTH (normal values 10—65 pg/mI)
D E F
Treatment All patients Responders Non-responders P
time (N = 76) (N = 58) (N = 18) E vs. F
A 0 767 76 793 93 642 106 NS
B 2 months 441 39 408 43 593 84 <0.02
C 4 months 509 52 411 50 825 124 <0.001
A vs. B P < 0.0000001 P < 0.0000001 P: NS
Avs.C P<0.0000I P<0.00000001 P<0.0001
Plasma aluminum concentrations were also determined in a
subset of 18 patients (from the dialysis units in Milano).
There were no differences in deviation from the protocol
among the five dialysis centers.
Serum calcium, phosphorus, magnesium, albumin and alka-
line phosphatase were determined with the use of automated
methods. Ionized calcium was measured by an ion-specific
flow-through electrode. Plasma aluminum was measured by
flameless electrothermal atomic absorption spectrometry, Se-
rum PTH was determined with an RIA recognizing the intact
hormone (iPTH) [12] and with an RIA recognizing mid-region
PTH (mPTH) [131. To increase the precision of PTH levels
determination, all samples of the same patient (times zero, 2
months and 4 months) were measured simultaneously in dupli-
cate in the same assay. Moreover, all samples for PTH deter-
mination were centralized in a single laboratory (iPTH in
Ferrara, mPTH in Milano). Intra-assay and inter-assay varia-
tions of PTH measurement were respectively 2.6% and 5.9%for
iPTH, and 6.4% and 11% for mPTH.
The results are expressed as mean standard error of the
mean (5EM). For statistical analysis, Student's f-test for paired
data and a pooled estimate of variance analysis for comparison
of the means between different groups were used.
Results
Seven out of 83 (8%) patients dropped out during treatment:
three of them refused to continue treatment complaining side
effects probably not related to calcitriol administration, such as
excessive weight gain; and four patients were dismissed be-
cause of persistently elevated calcium phosphate products (one
of them underwent parathyroidectomy). Seventy-six patients
completed the study: 20 in Genova, 17 in Ferrara, 18 in Milano,
21 in Como.
Intact PTH levels decreased significantly in the overall pop-
ulation during treatment with intravenous calcitriol (Table 1).
However, some patients did not show a reduction of PTH
concentrations and based on an arbitrary distinction, that is, the
decrement or increment of iPTH levels after four months of
treatment, we divided our patient population in a responder
group (58 of 76 patients, 76% of total) and a non-responder
group (18 of 76 patients, 24% of total). The reason for this
choice was trying to understand which factor(s) could be
responsible for the lack of response to treatment.
The two groups did not differ in terms of age or duration of
dialysis. The non-responders were 6 of2l (28.6%) in Como, 3 of
Values are given as mean SEM.
A vs. B, A vs. C: paired t-test; E vs. F: pooled estimate of variance
analysis.
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Table 2. Mid-region PTH levels during intravenous calcitriol therapy
Mid-region_PTH (normal values 0.2—0.6 ng/mI)
D E F
Treatment All patients Responders Non-responders P
time (N = 76) (N = 58) (N = 18) E vs. F
A 0 5.88 0.45 5.62 0.45 6.71 1.25 NS
B 2 months 4.87 0.39 4.70 0.44 5.40 0.84 NS
C 4 months 5.70 0.45 5.26 0.50 7.10 0.90 <0.05
A vs. B P < 0.0000001 P < 0.000001 P < 0.02
A vs. C P: NS P < 0.05 P: NS
Values are given as mean SEM.
A vs. B, A vs. C: paired 1-test; E vs. F: pooled estimate of variance
analysis.
Table 3. Total calcium levels during intravenous calcitriol therapy
Total calcium (normal values_8.5—10.Smg/dl)
D E F
Treatment All patients Responders Non-responders P
time (N = 76) (N = 58) (N = 18) E vs. F
A 0 9.07 0.08 9.05 0.09 9.10 0.16 NS
B 2 months 9.46 0.14 9.45 0.17 9.48 0.25 NS
C 4 months 9.58 0.10 9.67 0.10 9.27 0.27 NS
A vs. B P < 0.01 P < 0.02 P < 0.05
A vs. C P < 0,000001 P < 0.00000001 P: NS
Values are given as mean SEM.
A vs. B, A vs. C: paired I-test; E vs. F: pooled estimate of variance
analysis.
Table 4. Ionized calcium levels during intravenous calcitriol therapy
Ionized calcium (normal values 4.5—5.5
______
mg/dl)
______
D E F
Treatment All patients Responders Non-responders P
time (N = 76) (N = 58) (N = 18) E vs. F
A 0 4.84 0.04 4.88 0.04 4.76 0.08 NS
B 2 months 4.92 0.05 4.96 0.04 4.76 0.08 <0.02
C 4 months 4.88 0.04 4.92 0.04 4.80 0.12 NS
A vs. B P < 0.05 P < 0.02 P: NS
A vs. C P: NS P: NS P: NS
Values are given as mean SEM.
A vs. B, A vs. C: paired 1-test; E vs. F: pooled estimate of variance
analysis.
17 (17.6%) in Ferrara, 5 of 18 (29.4%) in Milano, and 4 of 20
(20%) in Genova. The mean iPTH values of the different groups
are reported in Table 1. Intact PTH decreased by 34% in the
overall population, and by 48% in the responder group.
Mid-region PTH levels behaved differently. A significant
decrease was observed after two months of treatment, but no
differences could be detected at four months (Table 2).
Total serum calcium increased slightly but significantly in the
responder group and remained unchanged in the non-respond-
ers (Table 3), however, it should be pointed out that the mean
calcium levels remained well below 10 mg/dl.
Ionized calcium also showed a trend to increase in the
responder group, but no significant changes could be detected
after four months of treatment (Table 4).
Table 5. Phosphate levels during intravenous calcitriol therapy
Phosphate (normal values 3.0—4.5 mg/dl)
D E F
Treatment All patients Responders Non-responders P
time (N = 76) (N = 58) (N = 18) E vs. F
A 0 4.95 0.13 5.04 0.14 4.68 0.31 NS
B 2 months 5.12 0.15 5.30 0.17 4.51 0.24 <0.02
C 4 months 5.30 0.14 5.47 0.17 4.72 0.18 <0.02
A vs. B P: NS P: NS P: NS
A vs. C P < 0.01 P < 0.01 P: NS
Values are given as mean SEM.
A vs. B, A vs. C: paired 1-test; E vs. F: pooled estimate of variance
analysis.
Table 6. Alkaline phosphatase levels during intravenous calcitriol
therapy
Alkaline phosphatase (normal values 60 to
170 U/liter)
D E F
All patients Responders Non-responders P
________
(N = 76) (N = 58) (N = 18) E vs. F
3l0 39 302 46 335 69 NS
291 44 268 52 364 76 NS
251 37 225 40 336 82 NS
Values are given as mean SEM.
A vs. B, A vs. C: paired 1-test; E vs. F: pooled estimate of variance
analysis.
Serum albumin was slightly different in the two groups: in
responders it was 3.9 0.04 g/dl (time zero), 4.3 0.07 gIdl (2
months), and 4.4 0.06 g!dl (4 months), while in non-respond-
ers it was 3.9 0.07 g/dl (time zero), 4.2 0.09 g/dl (2 months),
and 4.0 0.08 g/dl (4 months). Such differences can justify in
part the increase in total calcium, without a concomitant
increase in ionized calcium.
Serum phosphorus tended to increase during treatment (Ta-
ble 5). The amount of phosphate binders administered to the
patients was adjusted to maintain the levels of serum phospho-
rus below 6 mgldl. It is noteworthy, however, that a significant
increase could be detected only in the responder group.
Serum magnesium did not change significantly during treat-
ment. It was 2.47 0.06 mg/dl at time zero and 2.55 0.06
mg/dl after four months of treatment in the total population.
Also, no differences could be detected in the responder and
non-responder groups.
At the end of the treatment period, the serum alkaline
phosphatase levels were significantly lower in the responder
group and remained unchanged in the non-responders, although
no significant difference could be found between the two
groups, probably because of very high SEM (Table 6).
Aluminum levels, measured in a subset of 18 patients, were
19.9 3.0 .tgIliter at time zero, 24.3 2.5 pg/liter at two
months, and 25.4 6.8 g/1iter at four months of treatment.
They remained unchanged in all but in one patient who, in order
to control serum phosphate, had to introduce and progressively
increase the amount of aluminum gels, up to 5 g!day. In this
Treatment
time
A 0
B 2 months
C 4 months
A vs. B
A vs. C
P:NS P:NS
P<0.Ol P<0.001
P: NS
P: NS
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Table 7. Calcium times phosphate products during intravenous
calcitriol therapy
Ca x P (normal values < 60)
D E F
Treatment All patients Responders Non-responders P
time (N = 76) (N = 58) (N = 18) E vs. F
A 0 44.9 1.3 45.5 1.3 43.0 3.4 NS
B 2 months 48.1 1.2 49.7 1.3 43.2 3.0 <0.05
C 4 months 50.7 1,5 52.9 1.7 43.8 2.1 <0.01
A vs. B P < 0.05 P < 0.01 P: NS
A vs. C P < 0.0001 P < 0.0001 P: NS
Values are given as mean
A vs. B, A vs. C: paired t-
SEM.
test; E vs. F: pooled estimate of variance
analysis.
Table 8. Episodes of hypercalcemia (total calcium > 11 mg/dl),
calcium times phosphate product > 60, and time spent off calcitriol
treatment during 4 months of intravenous calcitriol therapy, based on
weekly plasma calcium and phosphate determinations
Number
Responders(N = 58) Non-responders(N = 18)
Ca > 11 mg/dl Of episodes
Episodes/patient in
4 months
18
0.3
IS
0.8
Ca x P > 60 Of episodes
Episodes/patient in
4 months
45
0.8
37
2.1
Time spent off Of dialysis sessions 35 28
calcitriol Dialysis/patient 0.6 1.6
patient a remarkable increase in serum aluminum could be
detected, from 14 pg/liter (time zero) to 49 pg/liter (2 months),
to 134 sg/1iter (4 months).
As far as the side effects are concerned, intravenous calcitriol
was very well tolerated by all patients. However, besides the
four above-mentioned patients who interrupted treatment be-
cause of persistently elevated calcium phosphate products, 60%
of patients presented at least once in four months phosphate
levels over 6 mgldl; 28 of 76(37%) reduced the dose of calcitriol
because their calcium times phosphate product exceeded 60.
Table 7 shows the calcium times phosphate products at times
zero, two and four months. They reflect the increases observed
in total calcium (Table 3) and phosphate (Table 5) levels.
However, the number of hypercalcemic episodes as well as the
number of episodes in which a calcium times phosphate product
over 60 was observed at the weekly determinations during the
four months of treatment was higher in non-responders, who
also spent more time off treatment (Table 8). Non-responders
had therefore to reduce their dose in a greater proportion than
responders (Table 9). Moreover, such episodes tended to occur
early during treatment. The use of a lower dose of calcitriol in
non-responders could therefore be responsible for the differ-
ence in calcium and phosphate levels detected at two and four
months of treatment.
The mean initial dose of calcitriol was 0.87 pg/dialysis. It was
decreased during treatment and at four months was 0.74 ,.tg/
dialysis (Table 10). The responder group received a mean dose
significantly higher than the non-responders, confirming that
the response to calcitriol of the parathyroid glands is dose
Table 9. Patterns of dose reductions
N of patients who reduced calcitriol dose
0—2 2—4
months months Total %
Responders 7
Non-responders 11
9
I
16/58
12/18
27.6
66.7
Responders reduced their dose in a lower proportion and during the
second half of the treatment period, while non-responders had to reduce
their dose early during treatment.
Table 10. Mean dose of intravenous calcitriol during treatment
Treatment
time
/.Lg
D
All patients(N = 76)
E
Responders(N = 58)
F
Non-responders(N = 18)
P
E vs. F
A 0
B 2 months
C 4 months
0.87 0.02
0.82 0.04
0.74 0.03
0.90 0.02
0.88 0.04
0.77 0,03
0.77 0.04
0.65 0.05
0.65 0.05
<0.01
<0.01
<0.05
A vs. B
Avs.C
P: NS
P<0.0000l
P: NS
P<0.000l
P < 0.02
P<0.02
Values are given as mean SEM.
A vs. B, A vs. C: paired 1-test; E vs. F: pooled estimate of variance
analysis.
dependent. Also, the difference in the amount of calcitriol
administered appears to be the only significant factor responsi-
ble for the lack of response to treatment in the non-responders
group, suggesting that a dose inferior to 0.75 pg/dialysis is likely
to be inadequate in most patients.
Asymptomatic hypercalcemia (total serum calcium over 11
mg/dl) occurred in a minority of patients (Table 8) and was
quickly reversed by temporarily halting treatment and decreas-
ing the dose. Among 22 patients who were taking calcium
carbonate as the only phosphate binder at the beginning of
treatment, 8 (36%) developed transient hypercalcemia, while 12
(55%) had to introduce an aluminum binder to control their
phosphate levels.
Discussion
The introduction of intravenous calcitriol in the treatment of
secondary hyperparathyroidism in hemodialysis patients has
been accompanied by enthusiasm because of the impressive
response to such treatment even in patients whose osteitis
fibrosa was refractory to oral calcitriol [7, 8].
High serum peak levels and greater bioavailability achieved
with the intravenous route may account for an enhanced
biologic effect at the parathyroid gland receptors, while a
reduced activity at the intestinal receptors may account for a
lower hypercalcemic effect of the intravenously administered
calcitriol [7, 14].
A major unanswered question about calcitnol therapy is the
actual clinical advantages of the intravenous over the oral
administration. To date, no comprehensive studies are available
to compare the action of oral as opposed to intravenous
calcitriol. Quarles et al [15] obtained marked suppression of
PTH levels in the absence of hypercalcemia by providing
adequate dietary calcium supplementation and normalizing
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serum concentrations of 1 ,25-dihydroxycholecalciferol. It is
difficult to compare the two treatment modalities, because with
the oral administration calcitriol has been given once or more
than once per day, while intravenous calcitriol has been admin-
istered three times per week at the end of dialysis. Moreover,
both the individual dose of calcitriol and the average dose per
week have been different. This study was not planned to
compare the oral versus the intravenous route, but we admin-
istered a mean starting dose of 0.9 g three times per week,
which corresponds to less than 0.5 sgIday, a quantity similar to
oral doses.
Such treatment proved to be effective in the majority of
patients and was not accompanied by relevant side effects.
However, we should consider that patients who showed a
decrease in PTH levels were treated with higher doses than
those who did not improve (Table 10). Moreover, as calcitriol
dose was reduced and maintainedat half the starting dose when
even occasionally the calcium-phosphate product exceeded 60,
a rebound rise in serum PTH was observed.
The absence of a concurrent control group in our study,
treated with oral calcitriol or with a higher dose of intravenous
calcitriol does not allow us to conclude that low-dose intrave-
nous calcitriol is more effective than other treatment modalities.
A comparison of our results with previous studies can be made
at two different levels: the route of administration and the dose
used.
In hypocalcemic patients with secondary hyperparathyroid-
ism, the use of calcium supplements and oral calcitriol often
results in an effective lowering of serum PTH levels [15].
However, in patients with normal or elevated serum calcium
concentration, the usefulness of such treatment is limited,
because relatively low doses of calcitriol induce hypercalcemia
and hyperphosphatemia. Because calcitriol directly inhibits the
secretion of PTH in a dose dependent manner [5, 6, 9, 16, 17],
the use of intravenous calcitriol has been considered an alter-
native treatment with the theoretical advantage of achieving
higher circulating calcitriol concentrations, reducing at the
same time its intestinal action. Slatopolsky et al [7] clearly
demonstrated the efficacy of intravenously administered cal-
citriol in suppressing PTH levels. They observed a 70% de-
crease in serum PTH in 20 hemodialysis patients, with a greater
effect in those with mild (86% decrease) and in moderate
hyperparathyroidism (73.5% decrease).
Intravenous calcitriol has been subsequently used for the
treatment of patients who could tolerate only small doses of oral
calcitriol therapy because of the development of hypercalcemia
[8].
In a small study (3 patients), Norris et al [18] compared oral
versus intravenous calcitriol and found a significant difference
in the reduction of PTH levels with similar concentrations of
serum calcium, suggesting that intravenous calcitriol is more
effective than daily oral treatment. On the other hand, more
recently Garrick et al [19] could not detect any difference in the
efficacy of intravenous and oral calcitriol in 14 hemodialysis
patients with secondary hyperparathyroidism. Moreover, in a
comparison of intravenous (3 pg/week) and pulse oral (10
pg/week) therapy, Gonzalez et al [20] found that pulse oral
calcitriol is well tolerated and is more effective than intravenous
calcitriol for the suppression of rTH levels in patients on
hemodialysis, although the higher dose of calcitriol used in the
patients receiving the pulse oral treatment also increased serum
calcium levels.
These studies suggest that both the dose and the circulating
concentration of calcitriol are important determinants of the
outcome of treatment. It is certain that equal amounts of
calcitriol administered oral or intravenously determine mark-
edly different serum concentrations, at least in the first two
hours. Serum calcitriol levels during the peak response after the
intravenous administration have been found approximately
fourfold higher in comparison with the values obtained after the
oral administration [7]. However, the actual clinical advantage
of such higher concentrations needs to be confirmed in the long
term.
There is much controversy and no clear indications on which
is the ideal dose of calcitriol for the treatment of secondary
hyperparathyroidism. A relevant question to be answered is
whether physiologic or pharmacologic concentrations are nec-
essary. Because suppression of PTH synthesis and secretion
proved to be dose dependent in vitro [9, 17], higher doses of
calcitriol should be more effective at lowering PTH levels. The
main factor limiting the use of high doses of calcitriol is the
occurrence of hypercalcemia or of an elevated calcium-phos-
phate product. The intraveious and the oral pulse administra-
tion of calcitriol allowed the use of higher doses (up to 12
pg/week) when compared to the traditional oral daily treatment,
gen,,rally achieving good control of secondary hyperparathy-
roidism [7, 8, 10, 18, 211. However, such therapeutic regimen
only rarely can be maintained for more than a few months. In
the pioneer study of Slatopolsky et al [7] the initial dose of
intravenous calcitriol was 0.5 j.sg and was gradually increased to
a maximum of 4.0 ig per dialysis session over a period of eight
weeks of treatment. The maximum dose of calcitriol adminis-
tered to each patient ranged from 1.75 to 4.0 g, while the final
dose ranged from 0.5 to 4.0 tg. These data suggest that even in
a short term study some patients could not be treated with high
doses, because of the occurrence of hypercalcemia or of an
elevated calcium-phosphate product. Moreover, in a pilot long-
term treatment (1 year) involving two patients, the dose of
intravenous calcitriol was reduced, ranging between 1.0 and 1.5
g, three times per week [7].
Another indirect evidence that some patients can not receive
high doses of intravenous calcitriol for a prolonged period of
time comes from the study by Rodriguez et al [22], in which six
hemodialysis patients were treated with calcitriol at the dose of
2 ,.g per dialysis for 42 weeks. To prevent the development of
hypercalcemia dialysate calcium was reduced to 2.5 mEq/liter,
as suggested by Slatopolsky et al [23]. The calcitriol dosage was
reduced only if the serum calcium exceeded 10.5 mg/dl, and this
occurred only in one patient after 38 weeks of treatment.
Inadvertently, an elevated ca!ium-phosphate product was not
used as a criteria to withhc? i treatment or to decrease the
dosage. Through this error, we learn that in five out of six
patients the mean serum phosphate between weeks 10 and 42 of
treatment was greater than 6.7 mg/dl, ranging from 6.76 to 11.28
mg/dl (12 to 20 determinations for each patient). Interestingly,
in two patients with phosphate levels greater than 10 mgldl,
PTH levels increased despite the presumed presence of high
circulating levels of calcitriol [22].
Again, this study shows that some patients (at least 50% in
this small population) do not tolerate high doses of intravenous
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calcitriol. Yudis, Sirota and Stein [241 also reported the occur-
rence of a calcium times phosphate product over 80 with rapid
metastatic calcification in a patient receiving high doses of
intravenous calcitriol. It is therefore tempting to speculate that
low dose intravenous calcitriol, coupled with a strict control of
phosphate levels by the use of calcium-based phosphorus
binders, could be in the long term a more rational treatment for
secondary hyperparathyroidism.
As discussed earlier, recent studies suggest that the higher
serum concentrations of calcitriol achieved with the intrave-
nous route and possibly with oral pulses may be of benefit in
preventing and treating secondary hyperparathyroidism. These
benefic effects are particularly an inhibiton of pre-pro-PTH
mRNA synthesis [5, 6], an increased sensitivity to calcium [101
and a direct effect on parathyroid hyperplasia [25, 26]. Another
theoretical advantage of the intravenous administration is that
oral calcitriol may stimulate local intestinal actions to a greater
extent than a comparable intravenous dose, resulting in greater
calcium and phosphate absorption. Moreover, calcitriol is me-
tabolized in the intestine [27]. This can further reduce the
fraction of orally administered calcitriol which is absorbed and
blunt the rise of plasma calcitriol concentrations.
With the intravenous administration, the patient's compli-
ance is assured for calcitriol. However, the frequent occurrence
of hyperphosphatemia observed in our study points out that the
patient's compliance for phosphate binders is not. Also, intra-
venous calcitriol does have intestinal actions, and similar pre-
cautions are needed for both intravenous and oral calcitriol
administration. We suggest calcium and phosphate levels be
monitored every two weeks, or more often when necessary.
Serial determinations of alkaline phosphatase, osteocalcin, and
PTH levels are also needed to monitor the response to treat-
ment and to avoid excessively low rates of bone turnover,
which predispose patients to an increased deposition of alumi-
num on mineralized bone surfaces [28]. The evaluation of whole
body stores of aluminum by means of a single infusion of
deferoxamine (DFO test) before starting calcitriol treatment
may also be helpful in identifying patients at risk for aluminum
bone disease [29, 30]. The reduction of the amount of calcium in
the dialysate may prevent the development of hypercalcemia in
patients treated with calcitriol [23]. Unfortunately, this measure
will not by itself reduce the frequency of hyperphosphatemia.
Treatment with calcium carbonate can avoid a negative calcium
balance and an excessive increase of phosphate absorption.
Therefore, even when using low dialysate calcium calcitriol
treatment should be coupled to large doses of calcium carbon-
ate and a strict control of serum phosphate levels, in order to
obtain a good control of secondary hyperparathyroidism [31].
In this study, patients who showed a decrease of iPTH levels
had final total serum calcium, phosphorus and ionized calcium
concentration well below the upper limit of normal. Due to the
high number of patients studied, clinically not relevant in-
creases of total calcium and phosphorus were statistically very
significant. A slight although not significant rise of ionized
calcium could also be observed. Therefore, we can state that
high serum calcitriol concentrations probably suppressed the
secretion and synthesis of PTH directly, with a modest effect on
circulating ionized calcium levels. However, an effect on the
intestinal absorption of both calcium and phosphorus is also
present and episodic hypercalcemia may have contributed to
the decline in serum PTH in some patients.
It has been pointed out that the effects of calcitriol to
suppress serum immunoreactive PTH levels have generally
been more marked when an intact PTH assay is used [32]. Our
study confirms this view, as with the mid-region PTH assay the
fall in PTH levels at two months was less pronounced although
highly significant, and at four months PTH levels were similar
to the starting values. The observed significant decrease of
alkaline phosphatase levels indicates that an improvement of
the excessive bone turnover may have occurred, and this
should be consistent with a reduction of PTH levels. A long-
term study on patients with symptomatic renal osteodystrophy
treated with oral calcitriol also showed a reduction of serum
alkaline phosphatase levels, improvement of bone pain and
muscular weakness, but no change in serum PTH, as measured
with a mid-region assay [331. In our experience, the radioim-
munoassay with antiserum recognizing the intact PTH molecule
appeared to be more sensitive in detecting changes in PTH
levels during treatment with calcitriol in hemodialysis patients.
Although serum phosphate levels could be adequately con-
trolled, the use of calcium carbonate in our patients was limited
because of the risk of inducing hypercalcemia. As already
suggested, the use of a 2.5 or a 3.0 mEq/liter dialysate calcium
could allow a safer use of either calcium carbonate or calcium
acetate, avoiding aluminum salts as phosphate binders [10, 23].
The introduction of new non-calcemic analogs of calcitriol [34]
could also hasten the disappearance of aluminum-containing
phosphate binders from the treatment regimens of uremic
patients.
In summary, intermittent treatment with low-dose intrave-
nous calcitriol may be effective in reducing serum PTH and
alkaline phosphatase levels in the absence of relevant side
effects. However, while patient compliance is assured for
calcitriol, it is not for phosphate binders. The frequent occur-
rence of asymptomatic hyperphosphatemia cautions against an
uncontrolled use of intravenous calcitriol, indicating that simi-
lar precautions are needed for both intravenous and oral cal-
citriol administration.
Finally, it remains to be established when treatment with
intravenous calcitriol should be started and which PTH level
should be the target of treatment: early treatment corrects very
effectively secondary hyperparathyroidism [10, 25], avoiding a
troublesome treatment of hypercalcemic patients with ad-
vanced hyperparathyroidism; on the other hand, normalization
of PTH levels could determine low rates of bone turnover,
predisposing patients to an increased deposition of aluminum
on mineralized bone surfaces and to impaired bone formation
[28]. The issue of the optimal PTH levels in patients undergoing
hemodialysis is controversial. Normal PTH levels have also
been associated with the occurrence of adynamic bone disease,
in the absence of aluminum accumulation [35]. In our patients,
the mean intact PTH levels remained substantially elevated and
did not decrease further from two to four months of treatment
with intravenous calcitriol. This might be due to the use of an
inadequate dose or to the presence of an interfering factor, such
as parathyroid hyperplasia or hyperphosphatemia. Other stud-
ies showed that calcitriol treatment often cannot return PTH
levels to normal [8, II]. Delmez et al [10] demonstrated that in
Gallieni et a!: Low-dose iv. calcitriol in dialysis patients 1197
patients with secondary hyperparathyroidism intravenous cal-
citriol could reduce PTH levels, but that even when maximal
suppression of the parathyroid gland was achieved with a
calcium infusion, PTH levels could not return to normal.
Therefore, parathyroid hyperplasia is probably limiting the
effect of calcitriol on PTH secretion and synthesis, although
recently it has been suggested that calcitriol treatment can
induce reversal of parathyroid hyperplasia by apoptosis [36].
It is difficult to establish if the dose we used is adequate. The
decrease in serum PTH is in our opinion the most reliable and
clinically most convenient parameter of response. The fact that
in the responders group no further decreases in PTH levels
could be observed from two to four months of therapy points to
a possible inadequacy of the dose, which indeed had been
reduced from 0.88 to 0.77 g!dialysis.
Besides PTH and alkaline phosphatase levels, other param-
eters of response to treatment, such as osteocalcin levels and
sequential bone biopsies, would be useful but were not assessed
in our study for logistics circumstances (high number of pa-
tients, different locations, duration of treatment).
We have assessed the effectiveness and safety of low-dose
intravenous calcitriol in hemodialysis patients. Further studies
comparing the oral and intravenous route are required to
establish if the theoretical advantages of intravenous calcitriol
will determine a better clinical management of renal osteodys-
trophy.
Based on the results of this study, we propose that the
starting dose should be 1 g at the end of dialysis and that this
dose should be maintained constant or possibly increased after
four to eight weeks of treatment only if serum PTH levels do not
decrease or if they show a rebound rise. A target serum calcium
of about 10 mg/dl should be achieved with the use of calcium
carbonate as a phosphate binder rather than with higher doses
of calcitriol. The calcium concentration in dialysate should be
adjusted to achieve an optimal control of phosphate levels
without inducing hypercalcemia.
An approach based on the use of low dose calcitriol could
also represent a way to reduce the cost of treatment with
intravenous calcitriol, which is more expensive than the oral
preparation.
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